{"filings":[{"id":95522,"accession_number":"0001193125-26-203993","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q1 2026: rinzimetostat RP3D for Phase 3; $419.7M cash; enozertinib data due 2H 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Rinzimetostat 400 mg QD + darolutamide data showed landmark rPFS 93%/84%/84% at 3/4/5 months; no Grade 4/5 TRAEs.","Cash and investments $419.7M as of March 31, 2026, including $59.9M from ATM. Expected runway into 2H 2028.","Enrolled Phase 1b enozertinib monotherapy in 1L EGFR exon20 insertion NSCLC; data expected 2H 2026.","R&D expenses $31.4M in Q1 2026 vs $24.6M in Q1 2025, driven by rinzimetostat and enozertinib advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108657,"accession_number":"0001193125-26-134618","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-03-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC provides rinzimetostat Phase 1b dose optimization update","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Update covers dose optimization data from Phase 1b trial of rinzimetostat (ORIC-944).","No numerical results or conclusions are disclosed in the 8-K filing itself.","Full data is included in the attached presentation (Exhibit 99.1) dated March 31, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108656,"accession_number":"0001193125-26-064291","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC files new $200M ATM offering; prior program fully utilized","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["New prospectus supplement filed Feb 26, 2026 for up to $200M in shares via Jefferies.","Prior $200M program (2024) terminated after raising $139.7M gross from 13.48M shares.","No further sales will be made under the 2024 prospectus supplement.","Legal opinion from Wilson Sonsini filed as Exhibit 5.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":108655,"accession_number":"0001193125-26-063974","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2026-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC reports Q4 2025 cash of $392.3M; positive Phase 1b data for rinzimetostat and enozertinib","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $392.3M at Dec 31, 2025; proforma $412.3M after $20M ATM in 2026; runway into 2H 2028.","Raised $264M from healthcare specialist funds in 2025 via private placement ($124.4M) and ATM ($117.6M).","R&D expenses Q4 2025 $25.9M (down 19% YoY); full year 2025 $109.8M (down 4% YoY).","Rinzimetostat Phase 1b: 55% PSA50, 20% PSA90, 76% ctDNA reduction; favorable safety vs competitors.","Enozertinib Phase 1b: 67% ORR in 1L EGFR exon20, 80% ORR in 1L EGFR PACC; 100% intracranial ORR."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125108,"accession_number":"0001193125-25-310472","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-12-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC presents enozertinib Phase 1b update; no specific results in filing","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company announced enozertinib (ORIC-114) program update on December 6, 2025.","Update covers data from Phase 1b trial; presentation attached as Exhibit 99.1.","No efficacy or safety figures included in the filing text itself.","Investors must refer to the separate presentation for detailed data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125107,"accession_number":"0001193125-25-280247","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ORIC updates ORIC-944 dose exploration data in corporate presentation","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["ORIC furnished updated ORIC-944 data slides for investor presentations (Exhibit 99.1).","No specific numerical data or endpoints from the slides were disclosed in the filing.","The presentation is for future use and does not contain financial results or guidance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":125106,"accession_number":"0001193125-25-280196","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q3 2025: $413M cash; ORIC-944 dose exploration complete with positive data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Cash and investments of $413M as of Sep 30, 2025; expected to fund operating plan into 2H 2028.","R&D expenses Q3 2025: $28.8M (down $2.4M YoY); G&A expenses: $7.9M (up $0.8M YoY).","ORIC-944 Phase 1b dose exploration completed; PSA50 in 55% (11/20), PSA90 in 20% (4/20), ctDNA clearance in 59% (10/17) mCRPC patients.","Provisional RP2Ds selected for ORIC-944 with darolutamide (400mg/600mg QD) and apalutamide (600mg/800mg/1200mg QD).","Appointed Kevin Brodbeck, PhD as Chief Technical Officer; enozertinib data expected at ESMO Asia Dec 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":141809,"accession_number":"0000950170-25-107313","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-08-12T23:59:59+00:00","items":["2.02","9.01","2.05"],"status":"ready","headline":"ORIC Pharma restructures, cuts 20% workforce, and extends cash runway to 2H 2028","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initiated strategic pipeline prioritization, eliminating discovery research and reducing workforce by ~20%; expects ~$1.9M one-time charge in Q3 2025.","Proforma cash and investments of $436.4M as of June 30, 2025, extending cash runway to 2H 2028 (previously 2H 2027).","Q2 2025 R&D expenses $30.5M (up from $28.9M), G&A expenses $8.5M (up from $7.1M); no revenue reported.","ORIC-944 Phase 1b data showed 59% PSA50 and 24% PSA90 responses; enozertinib (formerly ORIC-114) continues enrollment in NSCLC trials."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159722,"accession_number":"0001193125-25-140725","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-06-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ORIC shareholders elect two Class II directors; KPMG ratified as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["82.02% quorum (58.3M of 71.1M shares) represented at June 11 annual meeting.","Steven L. Hoerter elected with 48.5M for, 410.9K withheld; Angie You elected with 40.0M for, 8.9M withheld.","KPMG LLP ratified as independent auditor for FY2025 with 58.3M for, 44.9K against, 9.9K abstain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159721,"accession_number":"0001193125-25-129531","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-05-28T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"ORIC raises $125M; ORIC-944 Phase 1b shows 59% PSA50 response in mCRPC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["$125M private placement of 19.2M shares/pre-funded warrants at $6.50/share; led by SR One; close expected May 29, 2025.","Pro forma cash into 2H 2027 funds through first ORIC-944 Phase 3 registrational trial primary endpoint.","ORIC-944 + AR inhibitor achieved 59% PSA50 (10/17), 47% confirmed PSA50, and 24% PSA90 (4/17) in heavily pretreated mCRPC.","Safety mostly Grade 1/2 GI events (diarrhea 53%, one Grade 3); no Grade 4/5 treatment-related AEs.","Phase 1b dose optimization in 2H 2025; first global Phase 3 registrational trial expected to start in 1H 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":159720,"accession_number":"0000950170-25-063540","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q1 cash $224M; extends runway to 2027; plans Phase 3 for 2 programs in 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $223.8M at March 31, 2025; expected to fund operations into 2027 (vs previous guidance of late 2026).","R&D expenses $24.6M for Q1 2025, up from $22.0M YoY due to pipeline advancement and higher personnel costs.","Registrational plan for ORIC-944 in mCRPC: first Phase 3 trial targeted for 1H 2026; ORIC-114 Phase 3 in 1L NSCLC expected later in 2026.","Entered clinical trial collaboration with Johnson & Johnson for ORIC-114 plus subcutaneous amivantamab in 1L EGFR exon 20 NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178106,"accession_number":"0001193125-25-054784","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-03-14T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals amends inducement equity plan, adds 1.1M shares to reserve","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Compensation Committee approved Amended and Restated 2022 Inducement Plan, adding 1,100,000 shares to reserve.","Total shares reserved under the plan increased to 2,250,000 shares.","Amendment adopted without stockholder approval under Nasdaq Listing Rules.","Awards are inducement material for new employees and non-employee directors under Nasdaq Rule 5635(c)(4)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178105,"accession_number":"0001193125-25-035203","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-02-25T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"ORIC updates registrational plans for lead drugs, extends cash runway into 2027","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ORIC-944 first Phase 3 trial in mCRPC expected 1H 2026; combination dose escalation data in 1H and 2H 2025.","ORIC-114 registrational focus on 1L NSCLC with Phase 3 trials planned 2026; 2L/2L+ registration deprioritized.","Comprehensive NSCLC data update expected 2H 2025 including 1L EGFR exon 20 and atypical cohorts.","Cash, cash equivalents and investments totaled $256M as of Dec 31, 2024; projected runway extended into 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178104,"accession_number":"0000950170-25-022219","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-02-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q4/FY2024: $256M cash; R&D spend $114.1M; seven data readouts anticipated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash $256M as of Dec 31, 2024; expected to fund operations into late 2026.","R&D expenses Q4 $32.0M (up 31% YoY), FY2024 $114.1M (up 34%).","G&A expenses Q4 $7.6M (up 10%), FY2024 $28.8M (up 13%).","Expects seven data readouts for ORIC-114, ORIC-944 over 18 months; potential registrational trials in 2H25/early 2026.","Entered J&J collaboration for ORIC-114 + amivantamab in NSCLC; completed $125M private placement."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":178103,"accession_number":"0001193125-25-005028","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"ORIC Pharmaceuticals presents at JPM 2025; filing lacks specific data","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Company presented an updated corporate presentation at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025.","Presentation content not detailed in the filing excerpt; no new financial metrics or guidance provided.","No material changes or forward-looking statements were disclosed in the filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":194772,"accession_number":"0000950170-24-125386","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Q3 cash $282.4M, R&D up 39% YoY; ORIC-114 and ORIC-944 on track","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments of $282.4M as of Sep 30, 2024, expected to fund operations into late 2026.","R&D expenses $31.2M for Q3 2024 vs $22.4M in Q3 2023, increase of $8.8M (39%).","Presented preclinical data supporting best-in-class potential for ORIC-114 in EGFR exon 20 insertion NSCLC; Phase 1b data expected H1 2025.","Entered clinical trial collaboration and supply agreements with Bayer and Johnson & Johnson for ORIC-944 in prostate cancer.","Appointed Keith Lui as SVP of Commercial and Medical Affairs."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.32,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":211063,"accession_number":"0000950170-24-095419","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma Q2 cash $308.5M; ORIC-114 expansion and ORIC-944 combo dosing underway","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $308.5M as of June 30, 2024; expected to fund operations into late 2026.","R&D expenses $28.9M in Q2 2024 vs $18.8M Q2 2023, up $10.2M on pipeline advancement.","G&A expenses $7.1M in Q2 2024 vs $6.2M Q2 2023, up $0.9M on higher personnel costs.","ORIC-114 Phase 1b dose escalation complete; expansion cohorts in EGFR/HER2 mutant NSCLC dosed; data expected H1 2025.","ORIC-944 combo dosing initiated with NUBEQA and ERLEADA; clinical trial agreements with Bayer and J&J."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.83,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229567,"accession_number":"0001193125-24-161593","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"ORIC shareholders re-elect directors; ratify KPMG as auditor for FY2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Class I directors Richard Heyman (36.6M for, 11.9M withheld) and Lori Kunkel (48.0M for, 0.5M withheld) re-elected.","KPMG ratification passed: 55.6M for, 6,150 against, 338,222 abstain, no broker non-votes.","Meeting had 55.98M shares represented (83.02% of outstanding); record date April 17, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":229566,"accession_number":"0000950170-24-053551","cik":1796280,"company_name":"Oric Pharmaceuticals, Inc.","ticker":"ORIC","form_type":"8-K","filed_at":"2024-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"ORIC Pharma reports Q1 2024 cash of $331.5M; advances ORIC-114 and ORIC-944 trials","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $331.5M as of March 31, 2024, expected to fund operations into late 2026.","R&D expenses $22.0M in Q1 2024 vs $19.5M in Q1 2023; G&A $7.0M vs $6.2M.","Initiated three ORIC-114 Phase 1b expansion cohorts in NSCLC with EGFR/HER2 mutations; updated data expected H1 2025.","ORIC-944 initial Phase 1b data supports best-in-class profile; proceeding to combination with AR inhibitor in metastatic prostate cancer.","Strengthened cash with $125M private placement in January 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":888698268.8094407,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}